BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38142057)

  • 1. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation.
    Lee J; Turetsky J; Nasri E; Rogers SC
    BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38142057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peritoneal mesothelioma: the site of origin matters.
    Kindler HL
    Am Soc Clin Oncol Educ Book; 2013; ():182-8. PubMed ID: 23714495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members.
    Kittaneh M; Berkelhammer C
    J Transl Med; 2018 Jul; 16(1):194. PubMed ID: 30001711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
    Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
    Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
    J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.
    Nagata Y; Sawada R; Takashima A; Shoji H; Honma Y; Iwasa S; Amano K; Kato K; Hamaguchi T; Shimada Y; Saruta M; Boku N
    Jpn J Clin Oncol; 2019 Dec; 49(11):1004-1008. PubMed ID: 31287877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma.
    Lai J; Zhou Z; Tang XJ; Gao ZB; Zhou J; Chen SQ
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
    Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
    Lund-Andersen C; Nakken S; Nygård S; Fromm B; Aasheim LB; Davidson B; Julsrud L; Abrahamsen TW; Kristensen AT; Dybdahl B; Larsen SG; Hovig E; Flatmark K
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30862609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel BAP1 germline variant.
    Shinozaki-Ushiku A; Kohsaka S; Kage H; Oda K; Miyagawa K; Nakajima J; Aburatani H; Mano H; Ushiku T
    Pathol Int; 2020 Oct; 70(10):775-780. PubMed ID: 32583627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of diffuse malignant peritoneal mesothelioma.
    Hung YP; Dong F; Torre M; Crum CP; Bueno R; Chirieac LR
    Mod Pathol; 2020 Nov; 33(11):2269-2279. PubMed ID: 32504035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
    Glass C; Sholl LM; Landgraf JR; Chirieac L; Roggli VL
    Am J Surg Pathol; 2020 Feb; 44(2):288-292. PubMed ID: 31567203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
    Baumann F; Flores E; Napolitano A; Kanodia S; Taioli E; Pass H; Yang H; Carbone M
    Carcinogenesis; 2015 Jan; 36(1):76-81. PubMed ID: 25380601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of Peritoneal Mesothelioma In Situ to Invasive Mesothelioma Arising in the Setting of Endometriosis With Germline BAP1 Mutation: A Case Report.
    Fels Elliott DR; Travieso JL; As-Sanie S; Hrycaj SM; Lieberman RW; Myers JL; Huang T
    Int J Gynecol Pathol; 2022 Sep; 41(5):535-540. PubMed ID: 34723845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
    Shrestha R; Nabavi N; Lin YY; Mo F; Anderson S; Volik S; Adomat HH; Lin D; Xue H; Dong X; Shukin R; Bell RH; McConeghy B; Haegert A; Brahmbhatt S; Li E; Oo HZ; Hurtado-Coll A; Fazli L; Zhou J; McConnell Y; McCart A; Lowy A; Morin GB; Chen T; Daugaard M; Sahinalp SC; Hach F; Le Bihan S; Gleave ME; Wang Y; Churg A; Collins CC
    Genome Med; 2019 Feb; 11(1):8. PubMed ID: 30777124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion.
    Taylor S; Carpentieri D; Williams J; Acosta J; Southard R
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):e323-7. PubMed ID: 25222065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    Srinivasan G; Sidhu GS; Williamson EA; Jaiswal AS; Najmunnisa N; Wilcoxen K; Jones D; George TJ; Hromas R
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):861-867. PubMed ID: 28756516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Malignant mesothelioma and constitutional BAP1 gene mutations].
    Neviere Z; Berthet P; Polycarpe F; Dubos-Arvis C; Dô P; Gervais R
    Rev Mal Respir; 2019 Feb; 36(2):241-248. PubMed ID: 30686559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations.
    Hu ZI; Miettinen M; Quezado M; Lebensohn AP; Aldape K; Agra M; Wagner C; Mallory Y; Hassan R; Ghafoor A
    J Thorac Oncol; 2022 Mar; 17(3):461-466. PubMed ID: 34628055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.